Replies to post #303699 on Avid Bioservices Inc (CDMO)

[corporalagarn]

Can you or anyone else explain to me what successfully optimizing the assay means. It has success and optimize in it so that sounds good.

[asmarterwookie]

successfully optimized the assay

I wonder if "optimized" means the shrunk down equipment.

OH, also, I wonder where the human samples are coming from. NCCN network?

I sure wish Ronin didn't put so much emphasis on how terrible the APP is.

wook

[north40000]

Exosomes and Ovarian cancer: Does what the company below is doing represent a collaboration or competition with UTSW/PPHM?:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133225047

"...Arrayit Corporation and Avant Diagnostics, Inc. provide the market’s first large panel biomarker monitoring test for ovarian cancer (OVC). OvaDx® is advanced microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. Research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. Upon FDA approval, Avant will offer OvaDx® as an elective test for women seeking greater wellness and for women in the elevated risk category for ovarian cancer. OvaDx® will be used by doctors to advance the forefront of ovarian cancer treatment including improved surgical options, more effective chemotherapies, and to supplement existing tests including CA-125, OVA1®, and transvaginal ultrasound. ...."

I have asked before whether anyone knows if PPHM is working with company or companies above. No answer from anyone here or from PPHM.

Whatever, a million shares of ARYC purchased at $0.00275/share are quite profitable at the moment @ ~ $0.016.

[north40000]

I continue to wonder whether either UTSW/PPHM[exosomes to detect and diagnose, inter alia, Ovarian cancer initially] or CDMO have found multiple uses for this micro-array products line:

http://arrayit.com/Microarray_Diagnostics/Ovarian_Cancer_Forum/ovarian_cancer_forum.html

[biopharm]

7-14-17: Updates on the PS Exosomes Diagnostic Platform – from the Q4/FY17 earnings PR, the CC, and the 10K...

CJ, thanks for the exosomes update for Peregrine and now Avid Bioservices CDMO had all the IP assets that Ampersand is NOT being upfront to Avid shareholders

EVERYONE should demand answers from those at the ASM today because Ampersand now has New England Peptides with CEO Sam Massoni
under their wings ...listen to EXOSOMES, LIQUID BIOPS...etc and Early detection of cancer ..

John Springs Stafford just fleeced the shareholders into believing the IP Assets were not worthy and here is Ampersand Capital going ALL IN on EXOSOMES

Wake up investors ...the stock pps has been manipulated up to this point by more than one hedges working in synch as EXACT share trades have been submitted to the SEC and all should be complaining as they come after your shares of CDMO

New England Peptides - EXOSOMES with CEO Sam Massoni (short video explains below and after you hear, one should being irate that Ampersand Capital is using IP assets of Peregrine / Avid CDMO and profiting ..as CDMO pps manipulated in this range as the website speaks nothing about IP assets)

___________




New England Peptide Receives Growth Equity Investment From Ampersand Capital Partners
NEWS PROVIDED BY
Ampersand Capital Partners
Oct 08, 2019, 09:00 ET
GARDNER, Mass., Oct. 8, 2019 /PRNewswire/ -- New England Peptide, a leading provider of high-quality custom peptides and antibodies to the global life sciences market, today announced the majority recapitalization of the company by Ampersand Capital Partners. Ampersand's investment will be used to support the company's worldwide growth initiatives, including fueling the expansion of peptide synthesis capabilities to better serve an increasingly global customer base. As part of the transaction, New England Peptide also announced the appointment of Dr. José de Chastonay as Executive Chairman of the company's Board of Directors.

Founded in 1998 by Sam and Jennifer Massoni, New England Peptide has rapidly grown to become one of the industry's leading providers of high-quality custom research-grade peptides, stable-labeled bioanalytical peptide standards, custom antibodies, and catalog peptide products to the life sciences market worldwide. The company serves a premier roster of pharmaceutical and biotechnology companies and academic/research institutions and has successfully synthesized hundreds of thousands of custom peptides that consistently meet the highest standards of quality, service, and technical expertise.

Dr. de Chastonay is an experienced executive with more than 30 years of industry experience. He has served in a number of senior management and advisory roles within various API and research chemical manufacturing organizations, most recently as Chief Marketing Officer and Member of the Corporate Executive Committee at Bachem Holding AG. Additional senior executive experience includes service as President & CEO of Irvine Scientific and as President of Bachem Americas. Dr. de Chastonay earned his Ph.D. in medical microbiology from the University of Bern and his MBA from the European University in Montreux.

CEO and Founder Sam Massoni commented, "New England Peptide's partnership with Ampersand comes at an exciting time in the company's history. With assistance from Ampersand, New England Peptide is well-positioned to continue its growth trajectory and improve its position within the marketplace for custom peptide synthesis. We are also very excited to partner with José de Chastonay, who will bring valuable insight into our evolving growth strategy."

Eric Lev, a Partner at Ampersand, added, "New England Peptide is an excellent fit with Ampersand's investment strategy of investing in growth-oriented businesses with established leadership positions in specialty segments of the market. We are thrilled at the opportunity to partner with Sam, Jennifer and the entire New England Peptide team."

Dr. de Chastonay added, "I see numerous opportunities to leverage New England Peptide's quality position to perpetuate the company's stellar growth trajectory during the coming years. I am excited to have the opportunity to partner with the company's management team to drive the future success of the business."

About New England Peptide
Established in 1998, New England Peptide designs and manufactures peptide and antibody solutions for drug, vaccine and diagnostic development organizations worldwide. Headquartered in Gardner, MA, the company specializes in custom peptide synthesis, polyclonal antibody production, stable-labeled bioanalytical peptide standards, and catalog peptide products. New England Peptide operates in a 25,000 square foot facility with significant laboratory space to service all customer and regulatory requirements. Additional information about New England Peptide is available at www.newenglandpeptide.com.

About Ampersand Capital Partners
Founded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of its core healthcare sectors, including Avista Pharma Solutions, Brammer Bio, Confluent Medical, Genewiz, Genoptix, Talecris Biotherapeutics, and Viracor-IBT Laboratories. Additional information about Ampersand is available at www.ampersandcapital.com.